Investor Relations
Join us in revolutionizing personalized medicine and genomic healthcare
The Genomics Revolution is Here
The global genomics market is projected to reach $60+ billion by 2030, growing at 12% CAGR. Molecure is positioned at the intersection of three powerful trends: functional genomics, artificial intelligence, and precision medicine.
We're not just a genomics company—we're building the infrastructure for precision healthcare. Our proprietary functional genomics AI models, clinical partnerships, and integrated diagnostic platform create multiple revenue streams and defensible competitive advantages.
Founded by Danielle Stella, a visionary leader in computational biology and functional genomics with 15+ years of experience and 50+ peer-reviewed publications, Molecure combines scientific rigor with entrepreneurial innovation.
$60B+
Total Addressable Market
12%
Market Growth (CAGR)
50K+
Genomes Processed
95%
Clinical Accuracy
Diversified Revenue Streams
Multiple pathways to revenue and scale
Direct-to-Consumer
Subscription and one-time analysis products with margin profiles exceeding 70%
B2B Healthcare
Integration with hospitals, clinics, and health systems for clinical-grade genomic analysis
Enterprise Partnerships
White-label genomic analysis solutions for insurers and pharmaceutical companies
Research Licensing
Data licensing and research tools for academic and commercial partners
AI Model Licensing
Proprietary machine learning models for genomic interpretation and risk prediction
Pharma Partnerships
Drug development and pharmacogenomics consulting for pharmaceutical companies
Key Milestones & Achievements
Proven track record of execution and growth
2023
Founded with Seed Funding
Molecure founded by Danielle Stella with initial seed investment securing core team and infrastructure
2023 Q4
First 1,000 Genomes Processed
Reached operational milestone with 1,000+ genomes successfully sequenced and analyzed
2024 Q1
Series A Investment
Raised $8M Series A led by premier biotech VCs to scale operations and expand market reach
2024 Q2
Healthcare Partnership Launch
Signed first enterprise partnerships with major hospital systems and health networks
2024 Q3
50K+ Genomes Milestone
Processed 50,000+ genomes with 95%+ clinical accuracy and expanding international presence
2024 Q4
AI Model Patent Filed
Filed patents on proprietary AI models for genomic interpretation and risk stratification
Leadership & Team
World-class team with deep genomics and biotech expertise
Danielle Stella
Founder & CEO
PhD Computational Biology (Stanford), 15+ years genomics research, 50+ publications, former lead researcher at top genomics institutes
Dr. James Liu
Chief Science Officer
MD/PhD, Former head of genomics at major biotech firm, 25+ years in medical genomics and clinical pathology
Rachel Martinez
Chief Operating Officer
MBA Harvard Business School, 12+ years healthcare operations and scaling biotech companies from startup to acquisition
Investor Resources
Access our latest pitch deck, financial models, and market research
Ready to Invest?
Contact our investor relations team to learn more about Molecure and investment opportunities
Schedule a Meeting